Victory Capital Management Inc. Grows Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Victory Capital Management Inc. boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 60.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 650,751 shares of the biopharmaceutical company’s stock after acquiring an additional 243,940 shares during the quarter. Victory Capital Management Inc.’s holdings in Halozyme Therapeutics were worth $31,112,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the business. Torray Investment Partners LLC raised its position in Halozyme Therapeutics by 0.6% in the fourth quarter. Torray Investment Partners LLC now owns 55,611 shares of the biopharmaceutical company’s stock worth $2,659,000 after acquiring an additional 353 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock worth $85,254,000 after acquiring an additional 9,780 shares in the last quarter. Unified Investment Management purchased a new position in Halozyme Therapeutics in the fourth quarter worth $895,000. Smartleaf Asset Management LLC raised its position in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 197 shares in the last quarter. Finally, Fisher Asset Management LLC raised its position in Halozyme Therapeutics by 28.0% in the fourth quarter. Fisher Asset Management LLC now owns 414,719 shares of the biopharmaceutical company’s stock worth $19,828,000 after acquiring an additional 90,714 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 1.4 %

HALO opened at $60.98 on Monday. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm has a market cap of $7.51 billion, a P/E ratio of 17.78, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $65.53. The business’s fifty day simple moving average is $55.70 and its 200 day simple moving average is $54.73.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now directly owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 31,697 shares of company stock valued at $1,754,451 over the last quarter. Insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on HALO shares. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Benchmark restated a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.